Understanding the ICH Q3E Draft Guideline: Strengthening Extractables & Leachables Programs with Science Driven Toxicological Insight

The ICH Q3E Draft Guideline for Extractables and Leachables represents a step toward global harmonization in how the pharmaceutical industry evaluates and controls chemical species that may migrate from packaging, manufacturing components, or delivery systems into drug products. As therapies become more advanced and delivery systems more intricate, the need for a consistent, risk‑based approach to extractables and leachables (E&L) is incredibly important.

A More Structured, Risk‑Based Framework

The draft guideline outlines a lifecycle‑focused process for identifying, characterizing, and assessing E&L risks. It emphasizes the integration of ICH Q9 quality risk management principles, encouraging manufacturers to consider factors such as:

• Material composition and potential for chemical migration (or propensity to leach)
• Product type, route of administration, and patient population
• Manufacturing and storage conditions
• Toxicological relevance of identified compounds

This structured approach is designed to help organizations prioritize testing and focus resources where they matter most.

Clear Expectations for E&L Studies

Q3E provides detailed guidance on when and how to conduct extractables studies, leachables studies, and simulated leachable assessments. It also clarifies expectations around:

• Analytical method selection
• Establishing and justifying Analytical Evaluation Thresholds (AETs)
• Linking extractable profiles to actual leachables in the final product
• Managing uncertainty when toxicological data are limited

These elements are essential for building a defensible E&L strategy that aligns with regulatory expectations.

A Strong Emphasis on Toxicological Evaluation

One of the most impactful aspects of the guideline is its focus on toxicological risk assessment. The draft outlines a framework for evaluating the safety of detected compounds, including considerations for:

• Deriving acceptable exposure limits, particularly for various routes of exposure
• Addressing vulnerable populations (i.e., pediatric and geriatric populations)
• Applying weight‑of‑evidence approaches when data are incomplete

This is an area where specialized expertise can significantly strengthen the overall E&L program. Interpreting complex datasets, navigating data gaps, and applying scientifically sound toxicological principles are critical to ensuring patient safety and regulatory confidence.

Lifecycle Management and Change Control

Q3E reinforces that E&L control is not a one-time exercise. Changes in formulation, components/materials, suppliers, or manufacturing processes may require reassessment. The guideline encourages proactive planning and documentation to ensure that E&L risks remain well‑managed throughout the product lifecycle.

How Intrinsik Corp. Supports This Evolving Landscape

As organizations adapt to the expectations outlined in Q3E, many are looking for scientific partners who can help interpret data and author robust, defensible toxicological risk assessments. Intrinsik’s team has substantial experience evaluating E&L across a wide range of product types — from small molecules and biologics to combination products with advanced delivery systems.

Our work often involves:

• Interpreting analytical data in a regulatory context
• Deriving exposure limits and safety thresholds
• Conducting literature reviews and risk assessments
• Supporting the development of E&L strategies and documentation

This scientific support helps companies align with emerging global expectations while maintaining a strong focus on patient safety.